Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo

Less than a year after scoring a fast FDA OK for its pioneering acute myeloid leukemia drug gilteritinib, Astellas has snapped up a positive recommendation from European regulators following an accelerated assessment.